Sun Pharma announces approval to mkt generic Cerebyx

20864 Investors following Sun Pharma. Share this News with them.

0

Like this story, share it with millions of investors on M3

Sun Pharma announces approval to mkt generic Cerebyx

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted approval for the Abbreviated New Drug Application (ANDA) to market a generic version of Parke Davis’s Cerebyx®, fosphenytoin sodium injection.

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Sun Pharma announces approval to mkt generic Ethyol Sun Pharma gets approval for generic Gemzar injection Sun Pharma gets approval to mkt generic Demadex tablets ALSO READ See latest News about Sun Pharma See previous management interviews See what other Experts & Brokerages are saying about Sun Pharma Sun Pharma BSE | NSE 25/05/12 Are Mutual Funds betting on Sun Pharma? Other Stocks in this news Parke Davis (India) |

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted approval for the Abbreviated New Drug Application (ANDA) to market a generic version of Parke Davis 's Cerebyx®, fosphenytoin sodium injection.

This fosphenytoin sodium injection USP, 50 mg PE*/ mL, is therapeutically equivalent to Parke Davis's Cerebyx®, and is available in two packs: 100 mg PE*/ 2 mL and 500 mg PE*/ 10 mL single dose vials. (PE*= Phenytoin sodium equivalents).

Fosphenytoin sodium injection has annual sales of approximately USD 15 million in the US.

Fosphenytoin sodium is used for the control of generalized convulsive status epilepticus as well as for prevention and treatment of seizures occurring during neurosurgery.

This product will reach the market shortly.

Sourced From: Sun Pharmaceutical Industries Ltd